medicaid glp-1 coverage Did you know? Approximately 36% of Ohioans are dealing with obesity. Addressing this challenge requires modern, science-based solutions. medications are helping patients reduce weight, lower their risk of chronic disease, and Save on GLP-1s with SingleCare

A safe prescribing decision also considers: eligibility and NHS pathway availability comorbidities and concurrent medicines tolerability and dose escalation patient preference and expectations capacity for follow-up and monitoring The difference between semaglutide and tirzepatide should therefore be framed as a clinical comparison, not a direct consumer recommendation

Remaining Challenges in ePA for GLP-1s While ePA greatly reduces friction, some challenges remain: Incomplete Payer Connectivity: Not every insurer will accept ePA for every drug/plan

A 2024 retrospective cohort study by Lu et al., using the TriNetX database, evaluated outcomes in BC patients with obesity treated with GLP-1 RAs compared to other weight loss medications

These potential confounders were identified by Read and SNOMED-CT codes in the CPRD and ICD-10 codes in HES APC

Research shows no permanent metabolic damage from cycling GLP-1 therapy on and off

Step by step, she said, priority should go to those at highest risk. When asked how far that prioritization could stretch, she pointed to Wegovys (semaglutide) expanding list of trials